In Rosenberg R, Baladi M, Bron M. Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea. J Clin Sleep Med. 2021; 17(4):711–717 published in the April 1, 2021 issue of Journal of Clinical Sleep Medicine there was an error in the Discussion section (last sentence of the third paragraph [from the end of page 714 into the first sentence on page 715]). The corrected sentence is:
“In a study of participants with narcolepsy with cataplexy who received 7 weeks of treatment with pitolisant (3 weeks of flexible dosing [5 mg, 10 mg, or 20 mg], followed by 4 weeks of stable dosing [5 mg, 10 mg, 20 mg, or 40 mg]) or matching placebo, 39% of participants receiving pitolisant achieved ESS scores ≤ 10 compared with 18% of participants receiving placebo.27 The FDA-approved dosage range for pitolisant for treatment of narcolepsy in the US is 17.8 mg to 35.6 mg daily (which corresponds to 20 mg to 40 mg of pitolisant hydrochloride used in the study).14”
The authors regret this error.